Drug Profile
ANA 971
Alternative Names: ANA-971Latest Information Update: 21 Feb 2017
Price :
$50
*
At a glance
- Originator Anadys Pharmaceuticals
- Class Antivirals; Immunotherapies; Purine nucleosides
- Mechanism of Action Interferon stimulants; Natural killer cell stimulants; Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 19 Jun 2006 This programme is still in active development
- 01 Mar 2004 Phase-I clinical trials in Hepatitis C treatment in USA (PO)